NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $7.47 +0.18 (+2.47%) As of 12:03 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ocular Therapeutix Stock (NASDAQ:OCUL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ocular Therapeutix alerts:Sign Up Key Stats Today's Range$7.35▼$7.5350-Day Range$6.29▼$11.7352-Week Range$6.00▼$16.44Volume616,556 shsAverage Volume3.91 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$22.86Consensus RatingModerate Buy Company Overview Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications. Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis. These products are marketed in the United States. Ocular Therapeutix also develops investigational treatments for retinal and other eye diseases, including sustained-release implant programs designed to deliver medicines directly to the eye. The company was founded in 2006 and is headquartered in Bedford, Massachusetts. Antony Mattessich serves as its president and chief executive officer.AI Generated. May Contain Errors. Read More Ocular Therapeutix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreOCUL MarketRank™: 3.565441650545 of 5 starsOcular Therapeutix scored higher than 71% of companies evaluated by MarketBeat, and ranked 142nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOcular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOcular Therapeutix has a consensus price target of $22.86, representing about 203.7% upside from its current price of $7.53.Amount of Analyst CoverageOcular Therapeutix has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ocular Therapeutix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.47) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ocular Therapeutix's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.51% of the float of Ocular Therapeutix has been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 2.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentOcular Therapeutix has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Ocular Therapeutix this week, compared to 5 articles on an average week.Search InterestOnly 9 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $556,247.00 in company stock.Percentage Held by Insiders3.10% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCUL Stock News HeadlinesOcular Therapeutix™ to Participate in November Investor and Scientific ConferencesOctober 29 at 7:00 AM | globenewswire.comOcular Therapeutix: The Drug Won, The Stock Lost, And That's The OpportunityOctober 25, 2026 | seekingalpha.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.October 29 at 1:00 AM | Profits Run (Ad)Transcript : Ocular Therapeutix, Inc. - Special CallOctober 23, 2026 | marketscreener.comMOcular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing TranscriptOctober 23, 2026 | seekingalpha.comOcular Therapeutix (NASDAQ:OCUL) Stock Rating Reaffirmed as Buy by Needham & Company LLCOctober 21, 2026 | americanbankingnews.comOcular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS SaysOctober 20, 2026 | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Stock: Insider Peter Kaiser Sells 9,990 SharesOctober 7, 2026 | insidertrades.comSee More Headlines OCUL Stock Analysis - Frequently Asked Questions How have OCUL shares performed this year? Ocular Therapeutix's stock was trading at $12.14 at the beginning of the year. Since then, OCUL shares have decreased by 38.0% and is now trading at $7.5250. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings results on Monday, August, 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. The company's revenue for the quarter was down .1% on a year-over-year basis. When did Ocular Therapeutix IPO? Ocular Therapeutix (OCUL) raised $75 million in an IPO on Friday, July 25th 2014. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are Ocular Therapeutix's major shareholders? Ocular Therapeutix's top institutional shareholders include Deltec Asset Management LLC (1.19%), E. Ohman J or Asset Management AB (0.17%), Profund Advisors LLC (0.06%) and MGO One Seven LLC (0.02%). Insiders that own company stock include Summer Road Llc, Pravin Dugel, Antony C Mattessich, Donald Notman, Sanjay Nayak, Nadia Waheed, Jeffrey S Heier, Peter Kaiser, Richard L Md Lindstrom, Todd Anderman, Philip C Strassburger and Rabia Gurses Ozden. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Tesla (TSLA), Bristol Myers Squibb (BMY), Plug Power (PLUG) and Intel (INTC). Company Calendar Last Earnings8/03/2026Today10/29/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, OCUL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OCUL CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees325Year Founded2006Price Target and Rating Average Price Target for Ocular Therapeutix$22.86 High Price Target$30.00 Low Price Target$14.00 Potential Upside/Downside+205.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$265.94 million Net Margins-579.10% Pretax Margin-579.10% Return on Equity-59.89% Return on Assets-45.99% Debt Debt-to-Equity Ratio0.14 Current Ratio13.10 Quick Ratio13.03 Sales & Book Value Annual Sales$51.95 million Price / Sales31.60 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book2.43Miscellaneous Outstanding Shares219,620,000Free Float212,808,000Market Cap$1.64 billion OptionableOptionable Beta1.00 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:OCUL) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
